Suppr超能文献

命中(生物)标记物 第二部分:心血管研究中生物标志物数据的分析、解释和报告。

Hitting the (bio)mark Part 2: analysing, interpreting, and reporting biomarker data in cardiovascular research.

机构信息

School of Nursing and Knight Cardiovascular Institute, Oregon Health & Science University, 3455 S.W. U.S. Veterans Hospital Road | Mail code: SN-ORD, Portland, OR 97239-2941, USA.

KU Leuven Department of Public Health and Primary Care, KU Leuven-University of Leuven, Leuven, Belgium.

出版信息

Eur J Cardiovasc Nurs. 2024 Oct 21;23(7):818-824. doi: 10.1093/eurjcn/zvae020.

Abstract

Incorporating biomarkers into cardiovascular studies, including nursing research, is a common approach when identifying underlying mechanisms and providing targets for intervention. However, effective utilization of biomarker data demands careful consideration. In the analysis, interpretation, and reporting phase, there are many facets to consider, including non-normality of the data, normalization procedures, and potential confounding influences of other clinical data. Furthermore, as many studies focus on patient-reported outcomes (PROs), it is important that the analysis and interpretation of biomarkers in relation to PROs is rigorous and reproducible. In this article, Part 2 of 2, we provide an overview of considerations for the analysis, interpretation, and reporting phases of biomarker studies. We also provide an example of these steps.

摘要

将生物标志物纳入心血管研究,包括护理研究,是在确定潜在机制和提供干预靶点时常用的方法。然而,要有效利用生物标志物数据需要仔细考虑。在分析、解释和报告阶段,有许多方面需要考虑,包括数据的非正态性、标准化程序以及其他临床数据的潜在混杂影响。此外,由于许多研究都集中在患者报告的结果(PROs)上,因此严格且可重复地分析和解释与 PROs 相关的生物标志物非常重要。在本文的第 2 部分(共 2 部分)中,我们概述了生物标志物研究的分析、解释和报告阶段的注意事项。我们还提供了这些步骤的一个示例。

相似文献

1
Hitting the (bio)mark Part 2: analysing, interpreting, and reporting biomarker data in cardiovascular research.
Eur J Cardiovasc Nurs. 2024 Oct 21;23(7):818-824. doi: 10.1093/eurjcn/zvae020.
2
Hitting the (bio)mark part 1: selecting and measuring biomarkers in cardiovascular research.
Eur J Cardiovasc Nurs. 2024 Sep 5;23(6):690-695. doi: 10.1093/eurjcn/zvae014.
3
Identifying subgroups: Part 2: Trajectories of change over time.
Eur J Cardiovasc Nurs. 2020 Jun;19(5):444-450. doi: 10.1177/1474515120911330. Epub 2020 Mar 4.
5
Triangulation as a method for contemporary nursing research.
Nurse Res. 2005;13(2):71-82. doi: 10.7748/nr.13.2.71.s8.
8
Quantitative vs qualitative research.
Nurs RSA. 1991 Jan;6(1):14-8.
9
Randomization by cluster.
Nurs Res. 1991 Nov-Dec;40(6):356-8.
10
Case study: design? Method? Or comprehensive strategy?
Nurse Res. 2004;11(3):70-6. doi: 10.7748/nr2004.04.11.3.70.c6206.

本文引用的文献

1
Guidelines on the use of sex and gender in cardiovascular research.
Am J Physiol Heart Circ Physiol. 2024 Jan 1;326(1):H238-H255. doi: 10.1152/ajpheart.00535.2023. Epub 2023 Nov 24.
2
The Effects of Exercise on Telomere Length in Persons With Heart Failure.
J Cardiovasc Nurs. 2024;39(3):E86-E92. doi: 10.1097/JCN.0000000000001044. Epub 2023 Oct 6.
3
Impact of early pericardial fluid chymase activation after cardiac surgery.
Front Cardiovasc Med. 2023 Apr 12;10:1132786. doi: 10.3389/fcvm.2023.1132786. eCollection 2023.
4
Pro-Inflammatory Proteins Associated with Frailty and Its Progression-A Longitudinal Study in Community-Dwelling Women.
J Bone Miner Res. 2023 Aug;38(8):1076-1091. doi: 10.1002/jbmr.4861. Epub 2023 Jul 17.
6
Survival analysis 101: an easy start guide to analysing time-to-event data.
Eur J Cardiovasc Nurs. 2023 Apr 12;22(3):332-337. doi: 10.1093/eurjcn/zvad023.
7
Candidate biomarkers of physical frailty in heart failure: an exploratory cross-sectional study.
Eur J Cardiovasc Nurs. 2023 Mar 1;22(2):149-157. doi: 10.1093/eurjcn/zvac054.
8
The role of generalized linear models in handling cost and count data.
Eur J Cardiovasc Nurs. 2022 Jun 2;21(4):392-398. doi: 10.1093/eurjcn/zvac002.
10
Identifying subgroups: Part 2: Trajectories of change over time.
Eur J Cardiovasc Nurs. 2020 Jun;19(5):444-450. doi: 10.1177/1474515120911330. Epub 2020 Mar 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验